[Effect of a combination of teveten and prestarium in patients with chronic heart failure].
The safety and efficiency of the therapy with the angiotenzin-II receptor blocker--teveten were compared with the ACE inhibitor prestarium and their combination in patients with NYHA functional classes II-III of the chronic heart failure (CHF), who were on conventional therapy with diuretics and cardiac glycosides. The special attention was given to the influence of a combination of teveten and prestarium on morphofunctional performance of the myocardium and vessels, the neurohumoral status, quality of life and survival in patients with left ventricular dysfunction. Our study confirmed that Prestarium or Teveten monotheraphy gives approximately identical result, while their combination have better influence on the quality of life and hemodynamic parameters. The combined use of teveten and the ACE inhibitor prestarium is the most optimal treatment regimen in patients with moderate and severe CHF.
Gorgoshidze
M L
ML
Department of Cardiology, Georgian Medical Academy.
Abashidze
T B
TB
D000179:Acrylates / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D020913:Perindopril / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D000179:Acrylates; D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan; D020913:Perindopril